Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GEORGE HUTTON and RAJENDER APARASU.
GEORGE HUTTON
Connection Strength
3.159
RAJENDER APARASU
  1. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.248
  2. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2024 Nov 15.
    View in: PubMed
    Score: 0.248
  3. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.245
  4. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
    View in: PubMed
    Score: 0.236
  5. Assessing treatment switch among patients with multiple sclerosis: A machine learning approach. Explor Res Clin Soc Pharm. 2023 Sep; 11:100307.
    View in: PubMed
    Score: 0.226
  6. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
    View in: PubMed
    Score: 0.224
  7. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
    View in: PubMed
    Score: 0.210
  8. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
    View in: PubMed
    Score: 0.205
  9. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
    View in: PubMed
    Score: 0.200
  10. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Explor Res Clin Soc Pharm. 2021 Jun; 2:100021.
    View in: PubMed
    Score: 0.194
  11. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
    View in: PubMed
    Score: 0.192
  12. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Prefer Adherence. 2020; 14:2187-2199.
    View in: PubMed
    Score: 0.187
  13. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
    View in: PubMed
    Score: 0.183
  14. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
    View in: PubMed
    Score: 0.182
  15. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020 Dec; 16(12):1670-1676.
    View in: PubMed
    Score: 0.179
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.